Beck Bode LLC Invests $5.18 Million in CRISPR Therapeutics AG $CRSP

Beck Bode LLC bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 98,801 shares of the company’s stock, valued at approximately $5,181,000.

Several other institutional investors have also recently made changes to their positions in the company. Axxcess Wealth Management LLC boosted its holdings in shares of CRISPR Therapeutics by 6.2% in the 4th quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock worth $683,000 after buying an additional 764 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth about $918,000. Global Retirement Partners LLC boosted its holdings in shares of CRISPR Therapeutics by 58.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,545 shares of the company’s stock worth $81,000 after buying an additional 567 shares during the last quarter. Leonteq Securities AG purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth about $1,155,000. Finally, IFP Advisors Inc boosted its holdings in shares of CRISPR Therapeutics by 29.9% in the 4th quarter. IFP Advisors Inc now owns 1,250 shares of the company’s stock worth $66,000 after buying an additional 288 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 10,020 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the sale, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 3,182 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares in the company, valued at approximately $4,411,728.24. The trade was a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 42,749 shares of company stock valued at $2,100,723. 4.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CRSP has been the topic of a number of research analyst reports. Chardan Capital boosted their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Citizens Jmp cut their price target on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a report on Friday, January 30th. Piper Sandler reissued an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. Wall Street Zen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Morgan Stanley reissued an “underweight” rating and issued a $33.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $65.47.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $50.36 on Friday. The company has a market cap of $4.86 billion, a PE ratio of -8.10 and a beta of 1.74. CRISPR Therapeutics AG has a 52 week low of $35.38 and a 52 week high of $78.48. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. The firm’s 50-day simple moving average is $50.88 and its two-hundred day simple moving average is $53.26.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million during the quarter. Research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.